


Article

A Network of microRNAs Acts to Promote Cell Cycle Exit and Differentiation of Human Pancreatic Endocrine Cells



Wen Jin,
Francesca Mulas,
Bjoern
Gaertner, ...,
Andrea C.
Carrano, Hung-
Ping Shih, Maike
Sander

masander@ucsd.edu

HIGHLIGHTS

Genome-wide
identification of miRNAs
regulated in human
endocrine cell
development

Endocrine-enriched
miRNAs promote cell
cycle exit and endocrine
cell formation

Network modeling
predicts miRNA-regulated
TFs and downstream cell
cycle regulators

DATA AND CODE

AVAILABILITY

GSE115327
GSE52314
GSE51924
GSE54471
GSE51311

Jin et al., iScience 21, 681–694
November 22, 2019 © 2019
The Authors.
[https://doi.org/10.1016/
j.isci.2019.10.063](https://doi.org/10.1016/j.isci.2019.10.063)

Article

A Network of microRNAs Acts to Promote Cell Cycle Exit and Differentiation of Human Pancreatic Endocrine Cells

Wen Jin,¹ Francesca Mulas,¹ Bjoern Gaertner,¹ Yinghui Sui,¹ Jinzhao Wang,¹ Ileana Matta,¹ Chun Zeng,¹ Nicholas Vinckier,¹ Allen Wang,¹ Kim-Vy Nguyen-Ngoc,¹ Joshua Chiou,¹ Klaus H. Kaestner,² Kelly A. Frazer,³ Andrea C. Carrano,¹ Hung-Ping Shih,⁴ and Maïke Sander^{1,5,*}

SUMMARY

Pancreatic endocrine cell differentiation is orchestrated by the action of transcription factors that operate in a gene regulatory network to activate endocrine lineage genes and repress lineage-inappropriate genes. MicroRNAs (miRNAs) are important modulators of gene expression, yet their role in endocrine cell differentiation has not been systematically explored. Here we characterize miRNA-regulatory networks active in human endocrine cell differentiation by combining small RNA sequencing, miRNA over-expression, and network modeling approaches. Our analysis identified *Let-7g*, *Let-7a*, *miR-200a*, *miR-127*, and *miR-375* as endocrine-enriched miRNAs that drive endocrine cell differentiation-associated gene expression changes. These miRNAs are predicted to target different transcription factors, which converge on genes involved in cell cycle regulation. When expressed in human embryonic stem cell-derived pancreatic progenitors, these miRNAs induce cell cycle exit and promote endocrine cell differentiation. Our study delineates the role of miRNAs in human endocrine cell differentiation and identifies miRNAs that could facilitate endocrine cell reprogramming.

INTRODUCTION

The potential to generate pancreatic beta cells from human pluripotent stem cells (hPSCs) or via cell reprogramming from other cell sources holds promise for modeling causes of diabetes and cell replacement therapies (Benthuyesen et al., 2016). Knowledge of the molecular underpinnings of pancreas and beta cell development has enabled some success in developing beta cell reprogramming and directed differentiation strategies. In particular, the identification of transcription factors (TFs) governing cell fate decisions has been instrumental for cell reprogramming approaches (Benthuyesen et al., 2016). Although TFs play a major role in orchestrating gene expression changes during developmental transitions, recent evidence also shows significant roles for other regulators such as small RNAs.

MicroRNAs (miRNAs) are a group of small non-coding RNAs (~22 nucleotides) with known roles in the regulation of gene expression in development, mature cell function, and disease (Vidigal and Ventura, 2015). Studies in mice and zebrafish have demonstrated important roles for miRNAs in pancreatic endocrine cell development and beta cell function (Kaspi et al., 2014). Pancreatic progenitor cell-specific deletion of *Dicer1*, an enzyme that is universally required for the functional maturation of miRNAs, results in reduced endocrine cell numbers (Lynn et al., 2007), whereas *Dicer1* disruption in beta cells impairs insulin biogenesis (Melkman-Zehavi et al., 2011). At the level of individual miRNAs, *miR-375* (Kloosterman et al., 2007; Poy et al., 2009) and *miR-7* (Kredo-Russo et al., 2012; Latreille et al., 2014) have been identified as regulators of beta cell differentiation and function.

Generally, miRNAs are thought to repress target mRNAs and act by destabilizing mRNAs through base pairing between the miRNA seed sequence (nucleotides at position 2–8) and a complementary sequence in the target mRNA (Guo et al., 2010; Lim et al., 2005). However, recent evidence suggests that miRNAs can also activate gene expression (Jopling et al., 2008; Valinezhad Orang et al., 2014; Vasudevan et al., 2007). The effects of individual miRNAs on gene expression are generally small, which has led to the concept that miRNAs fine-tune gene expression rather than acting as genetic switches (Vidigal and Ventura, 2015). Consistent with this idea, miRNAs have been shown to promote cell differentiation and to facilitate cell reprogramming when force expressed in conjunction with lineage-determining TFs (Chen et al., 2004, 2006;

¹Departments of Pediatrics and Cellular & Molecular Medicine, Pediatric Diabetes Research Center, University of California, San Diego, La Jolla, CA 92093, USA

²Department of Genetics and Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA

³Department of Pediatrics, Institute for Genomic Medicine, University of California, San Diego, La Jolla, CA 92093, USA

⁴Department of Translational Research and Cellular Therapeutics, Diabetes and Metabolic Research Institute, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA

⁵Lead Contact

*Correspondence: masander@ucsd.edu

<https://doi.org/10.1016/j.isci.2019.10.063>



Dey et al., 2012; Lim et al., 2005; Nam et al., 2013; Yoo et al., 2011). Mechanistically, each miRNA has the ability to repress hundreds of mRNA targets, and multiple miRNAs often converge on a single pathway to promote a common developmental outcome (Lim et al., 2005; Vidigal and Ventura, 2015). Therefore, a comprehensive understanding of context-specific contributions of miRNAs to gene regulation requires a systems-level approach where all miRNAs and their targets are considered.

In this study we used genome-wide small RNA sequencing to identify candidate miRNAs with possible roles in human endocrine cell differentiation. By comparing miRNA profiles of hPSC-derived pancreatic progenitors and human cadaveric beta and alpha cells genome-wide, we identified miRNAs that are induced during endocrine cell differentiation. Through gain-of-function experiments during hPSC differentiation, we show that islet cell-enriched miRNAs act to promote cell cycle exit and hence islet cell differentiation. Integrating RNA-seq, CLIP-seq, and chromatin state data, we applied a network modeling approach to identify candidate miRNA-regulated TFs that explain the impact of islet cell-enriched miRNAs on cell cycle regulation during endocrine cell differentiation. Our findings provide a systems-level view of how miRNAs regulate human endocrine cell differentiation, which has implications for programming islet endocrine cells from hPSCs or other cell sources.

RESULTS

Identification of miRNAs Up-Regulated during Endocrine Cell Differentiation

To identify miRNAs that are regulated during pancreatic beta cell differentiation, we conducted genome-wide small RNA sequencing in pancreatic progenitor cells derived from CyT49 human embryonic stem cells (hESCs) (Figure S1) and primary beta cells isolated from cadaveric human islets by fluorescence-activated cell sorting (Kameswaran et al., 2014) (Figure 1A). Although both up- and down-regulated miRNAs could have roles in beta cell differentiation, we here focused on miRNAs that increase in expression during endocrine cell differentiation. By comparing expression levels of individual miRNAs in beta cells and pancreatic endoderm stage (PE) cells, we defined miRNAs induced during beta cell differentiation. This analysis revealed 14 miRNAs that were more highly expressed in beta cells than in PE cells (>5,000 sequence reads in beta cells; > 2.3-fold increase; Figure 1B and Tables S1A and S1B). With the exception of miR-127, miR-204, and miR-99b, the same miRNAs also exhibited higher expression in sorted alpha cells compared with PE cells (Figure 1C and Tables S1A and S1C), suggesting shared roles for most miRNAs in the development of both endocrine cell types. Among the miRNAs induced during endocrine cell differentiation were miR-375, miR-200a/c, and miR-7, which have reported roles in beta cell development, proliferation, function, and survival in mice (Belgardt et al., 2015; Kloosterman et al., 2007; Kredon-Russo et al., 2012; Latreille et al., 2014; Nieto et al., 2012; Poy et al., 2004, 2009; Wang et al., 2013). Most notable was the significantly higher expression of members of the Let-7 miRNA family in both beta and alpha cells compared with PE cells, including Let-7a, Let-7b, Let-7f, Let-7g, and miR-98 (Figures 1B and 1D and Tables S1A and S1B). We confirmed the results from the small RNA sequencing by comparing miRNA levels in PE cells and human cadaveric islets using the Taqman miRNA assay (Figure 1E).

Identifying miRNAs Regulating Human Endocrine Cell Differentiation

To identify mRNAs regulated by these miRNAs, we selected several miRNAs for over-expression in hESC-derived PE cells. We included the top three beta cell-enriched miRNAs (miR-375, miR-127, and Let-7a), as well as Let-7g and miR-200a, as they are highly induced during endocrine cell differentiation. miR-7 was not included because of its inhibitory role in endocrine cell differentiation in mice (Kredon-Russo et al., 2012).

To determine the effects of these miRNAs on gene expression, we next over-expressed Let-7g, Let-7a, miR-200a, miR-375, and miR-127 individually in hESC-derived PE cells (Figure 2A). For these studies, we chose PE cells derived from H1 hESCs because a recently published protocol showed very efficient differentiation of H1 hESCs into beta-like cells *in vitro* (Rezania et al., 2014). Since our genome-wide small RNA sequencing was performed in PE cells from CyT49 hESCs (Figure 1), we first confirmed that H1 and CyT49 hESC-derived PE cells have similar molecular features. Similar to CyT49 hESC-derived PE cells (Figure S1), 98% of H1 hESC-derived PE cells expressed the pancreatic progenitor marker PDX1 (Figures S2A and S2B). In addition, RNA-seq analysis showed highly concordant transcriptome profiles of H1 and CyT49 hESC-derived PE cells ($|R| > 0.92$; Figure S2C). Furthermore, we confirmed that Let-7g, Let-7a, miR-200a, and miR-375 were expressed at similarly low levels in H1 and CyT49 hESC-derived PE cells (Figure S2D).




Figure 1. Identification of miRNAs Up-Regulated during Endocrine Cell Differentiation of Human Pancreatic Progenitor Cells

(A) Workflow for genome-wide small RNA profiling of pancreatic progenitors (pancreatic endoderm, PE) and endocrine islet cells. PE cells were differentiated from human embryonic stem cells (hESCs), and human alpha and beta cells were isolated from cadaveric human islets by fluorescence-activated cell sorting (FACS).

(B and C) MA plots comparing miRNA expression levels in PE cells and beta cells (B) or PE cells and alpha cells (C). miRNAs with higher expression in beta and alpha cells than PE are indicated by red circles in B and C, respectively. Blue lines indicate 2-fold change in miRNA expression; yellow line indicates no change.

(D) Heatmap comparing expression levels in PE, alpha cells, and beta cells of the thirteen most highly enriched miRNAs in beta cells compared with PE cells.

(E) Relative expression of indicated miRNAs determined by Taqman qPCR in PE cells and human islets.

Data are shown as mean \pm S.E.M. ($n = 3$ biological replicates). ns, not significant; ** $p < 0.01$, *** $p < 0.001$; Student's t test. See also Figure S1 and Table S1.




Figure 2. Endocrine Cell-Enriched miRNAs Regulate Expression of Cell Cycle Genes in Pancreatic Progenitor Cells

(A) Workflow to identify genes repressed by each indicated miRNA after lentiviral transduction of hESC-derived pancreatic endoderm (PE) cells. Transduced cells were sorted based on mCherry after 48 h, RNA-seq analysis performed (n = 3 biological replicates), and down-regulated genes identified.

(B–F) Venn diagrams showing the overlap between genes down-regulated in islets (n = 3) compared with PE (n = 2) (blue) and genes repressed by Let-7g (purple, B), Let-7a (red, C), miR-200a (yellow, D), miR-375 (green, E), or miR-127 (light blue, F). Top five GO categories enriched among genes repressed by the miRNA and down-regulated in islets compared with PE are shown on the right.

(G) Venn diagram showing overlap between miRNA-repressed genes.

See also [Figure S2](#), [Tables S2](#), and [S3](#).

Inclusion of an mCherry reporter into the miRNA constructs allowed us to monitor transduction efficiencies in PE stage cultures and to isolate transduced cells by FACS. We observed 13%–20% mCherry⁺ PE cells 2 days after transduction, and this number increased to 34%–49% 6 days after transduction (Figure S2E). The increase is likely explained by the lentiviral expression vector requiring more than 2 days to reach maximum expression. To identify miRNA targets, we analyzed sorted mCherry⁺ PE cells 2 days after transduction, reasoning that this early time point is best suited for studying the direct effects of miRNA on gene expression. As expected, Let-7g, Let-7a, miR-200a, miR-375, and miR-127 were each expressed at significantly higher levels in cells transduced with the miRNA-expressing vector compared with control vector-transduced cells (Figure S2F). Furthermore, forced expression of Let-7g, Let-7a, miR-200a, miR-375, or miR-127 in hESC-derived PE repressed the expression of genes ($p < 0.05$, permutation test, Tables S2A–S2E) that were down-regulated between PE and islets (Figure S2G), suggesting that these miRNAs could contribute to gene expression changes during islet cell differentiation.

Islet Cell-Enriched miRNAs Regulate Expression of Cell Cycle Genes in Pancreatic Progenitor Cells

To identify miRNA-regulated transcripts with likely roles in endocrine cell differentiation, we analyzed sets of genes that were down-regulated by forced expression of each miRNA ($p < 0.05$, permutation test) and also down-regulated in islets as compared with PE cells ($p < 0.05$, permutation test, Figures 2B–2F). These mRNA subsets comprised 16.5% of Let-7g-, 13.9% of Let-7a-, 18.5% of miR-200a-, 18.7% of miR-375-, and 30.3% of miR-127-repressed mRNAs in PE cells. We then performed Gene Ontology (GO) analysis to define the biological processes regulated by mRNAs that are repressed by individual miRNAs and are also expressed at lower level in islet than PE cells. The top five enriched GO categories for each one of these miRNA-regulated sets of mRNAs comprised processes associated with DNA replication and regulation of the cell cycle (Figures 2B–2F and Tables S3A–S3E). Given that endocrine cell formation is associated with cell cycle exit (Kim et al., 2015; Miyatsuka et al., 2011; Piccand et al., 2014), these findings suggest that miRNAs could control endocrine cell differentiation by regulating mRNAs involved in cell cycle control. The finding that all five miRNAs regulate cell cycle-associated transcripts raised the question of whether they share similar target genes. Analysis of the extent of overlap between the mRNAs down-regulated by Let-7g, Let-7a, miR-200a, miR-375, and miR-127 revealed a modest number of shared targets (Figure 2G). Only seven mRNAs (*ZNF239*, *PIF1*, *CDC45*, *TMEM114*, *HIST1H4H*, *MRPS25*, and *ESPL1*) were repressed by all five miRNAs, indicating distinct regulatory roles for each one of the miRNAs. Together, these results suggest distinct but converging miRNA targets in regulating cell division in pancreatic progenitors.

Since all candidate miRNAs appeared to regulate different aspects of cell cycle progression, we sought to gain further insight into how input from the different miRNAs converges on cell cycle regulation. To study the combined effect of miRNAs, we generated a “polycistronic” miRNA (poly-miR) lentiviral construct that drives the expression of Let-7g, Let-7a, miR-200a, and miR-375 under the control of a single promoter. miR-127 was excluded because overall it repressed fewer genes than the other miRNAs (Figure 2F). We expressed the poly-miR construct in H1 hESC-derived PE cells and analyzed the transcriptome two days after transduction (Figure 3A). miRNA expression analysis in mCherry-sorted cells revealed that Let-7g, Let-7a, miR-200a, and miR-375 were each significantly higher expressed in poly-miR- than vector-only-transduced PE cells (Figures S3A and S3B). Expression of the poly-miR construct in PE cells resulted in down-regulation of 2,463 transcripts ($p < 0.05$; permutation test). Consistent with the results from expression of individual miRNAs (Figure S2G), poly-miR-repressed mRNAs ($p < 0.05$, permutation test, Table S2F) were highly enriched for mRNAs with higher expression in PE compared with islets (Figure S3C and Table S2G). Of the 2,463 poly-miR-repressed mRNAs, 388 were also down-regulated during the transition of PE to islet (Figure S3D). As predicted, genes involved in cell cycle processes were overrepresented among these 388 mRNAs (Figure S3D and Table S3F).

Endocrine-Enriched miRNAs Regulate Cell Cycle-Associated Transcription Factors

To decipher mechanisms by which Let-7g, Let-7a, miR-200a, and miR-375 regulate cell cycle genes, we sought to distinguish direct and indirect targets of the four miRNAs (Figure 3A). We defined putative direct targets as poly-miR-repressed mRNAs ($p < 0.05$, permutation test, Table S2F) predicted to be direct targets by TargetScan (based on matching sequence to the miRNA seed region) and/or exhibiting binding to the RNA-binding protein Argonaute, as determined by CLIP-seq in human islets (Kameswaran et al., 2014). From this analysis, 223 putative direct target mRNAs were identified (Figure 3B and Table S4A). Of these, all were predicted by TargetScan and 35 also by HITS-CLIP. These 223 genes represent 9.1% of




Figure 3. Identification of Putative Direct miRNA Target mRNAs in Pancreatic Progenitor Cells

(A) Workflow to identify repressed genes after transduction of hESC-derived pancreatic endoderm (PE) cells with a lentivirus expressing a polycistronic construct for the indicated miRNAs (poly-miR) and mCherry. Transduced cells were sorted after 48 h, RNA-seq analysis performed ($n = 3$ biological replicates), and down-regulated genes identified. Direct targets of candidate miRNAs were identified based on TargetScan and CLIP-seq analysis.

(B) Pie graph showing percentage of direct (dark gray) and indirect (light gray) targets of candidate miRNAs repressed by poly-miR construct.

(C) GSEA plot showing enrichment of 223 direct target genes of Let-7g, Let-7a, miR-200a, and miR-375 in islets ($n = 3$) compared with PE ($n = 2$). False Discovery Rate (FDR) is shown.

(D) mRNA expression levels of transcription factors directly targeted by Let-7g, Let-7a, miR-200a, and miR-375 measured in reads per kilobase per million reads mapped (RPKM).

(E) Predicted network of transcription factors downstream of miRNAs. Transcription factors are indicated by gray triangles, and individual miRNAs are indicated by colored squares.

See also [Figure S3](#), [Tables S2](#), [S3](#), and [S4](#).

all poly-miR-repressed genes. Reinforcing the potential relevance of these predicted direct miRNA targets for endocrine cell development, GSEA analysis showed significantly lower expression of these genes in islets than in PE cells (Figure 3C).

To determine whether miRNAs are direct regulators of cell cycle-associated mRNAs in PE cells, we analyzed enriched GO terms among the 223 predicted direct miRNA targets. We found no enrichment of categories linked to cell cycle-related processes (Table S4B). Moreover, many of the cell cycle regulators that were repressed by the poly-miR, including *CCND3*, *CDC45*, *MCM7*, and *CKS1B* (Table S2F), were not among the predicted direct miRNA targets (Table S4A). Thus, cell cycle-associated transcripts appear to be indirectly regulated by the miRNAs. We postulated that this indirect effect of miRNAs on the expression of cell cycle genes could be mediated through the regulation of TFs. Consistent with this hypothesis, 21 TFs were among the 223 putative direct miRNA targets (Figure 3D and Tables S4A and S4C). A striking finding was that many of these TFs have documented roles in cell cycle regulation, including *E2F2*, which is part of the complex controlling cell cycle progression, and numerous TFs are known to regulate cell growth (e.g., *ZC3H10*, *ZNF783*, *ZBTB46*, *ZBTB5*, *ZFYVE26*, *TP53*, *EZH1*, *HIF3A*, *DPF2*, *TEAD3*). In addition, TFs predicted to be directly regulated by the miRNAs included TFs involved in the regulation of endocrine cell development and maturation, such as *NKX6.1* (Schaffer et al., 2013; Taylor et al., 2013) and the thyroid hormone receptor *THRA*, consistent with the role of thyroid hormone in beta cell maturation (Matsuda et al., 2017). Reflective of their shared seed sequence, TFs that are predicted to be directly regulated by Let-7g and Let-7a showed complete overlap, whereas miR-200a and miR-375 mostly regulated separate sets of TFs (Figure 3E). This analysis indicates that Let-7g, Let-7a, miR-200a, and miR-375 might jointly change the transcriptional landscape in PE cells by down-regulating expression of different sets of TFs.

miRNAs Regulate a Network of Cell Cycle Genes in Pancreatic Progenitor Cells

Having identified a set of TFs as potential direct miRNA targets, we next sought to determine whether these TFs could act downstream of the miRNAs to regulate cell cycle genes. To test this, we constructed and subsequently probed a miRNA-gene regulatory network, linking the four candidate miRNAs and their putative direct TF targets to poly-miR-regulated genes predicted to be target genes of the TFs (Figures 4A, S4A, and S4B). First, to identify TF-binding events close to poly-miR-regulated genes (down- and up-regulated), we used ATAC-seq data from PE cells and islets and mapped open chromatin regions surrounding transcriptional start sites (TSSs; closest within 10 kb) of these genes ($n = 241,922$ sites; $FDR < 0.01$, MACS2) (Figures 4A and S4A; see Transparent Methods). Second, to pinpoint identified candidate TF-bound regions with likely impact on gene regulation during the PE to islet transition, we identified ATAC sites exhibiting dynamics in histone modifications between PE cells and islets. We focused on H3K4me3 and H3K27ac, two highly dynamic histone modifications during development (Wang et al., 2015; Xie et al., 2013) that have been associated with active promoters (H3K4me3) and active promoters and enhancers (H3K27ac) (Creighton et al., 2010; Heintzman et al., 2009). We then tested whether changes in these histone marks are accompanied by expression changes of proximal genes. As predicted, an increase in H3K4me3 and H3K27ac deposition in PE compared with islets was associated with higher mRNA levels ($p = 5.3 \times 10^{-134}$; Mann-Whitney test), whereas a decrease was associated with lower mRNA levels ($p = 1.9 \times 10^{-36}$). Finally, to construct the network, we linked open chromatin regions with dynamic histone marks to miRNA-regulated TFs by identifying those regions with a matching TF-binding motif. Validating our miRNA-gene regulatory network, GO analysis showed that the 1,307 genes comprising the network were enriched for cell cycle regulators (Figure S4C and Table S5).

Having validated our approach of linking putative TF binding events to changes in gene transcription during the PE to islet transition, we next assembled all data into a structured graph (Figures 4A and S4A) consisting of different types of nodes that represent the individual datasets, namely, the four candidate miRNAs (squares, Let-7g, Let-7a, miR-200a, and miR-375), their predicted target TFs (triangles), predicted TF-binding regions (hexagons), and indirect miRNA target genes (circles). Each connection between nodes (i.e., edge) was given a score representing the strength of their association, as inferred from miRNA-target databases (a), from algorithms matching TF motifs to DNA sequences (b), or from differential regulation of the connected gene (c) (see Figure S4A for details). A combined score was then computed for each possible path in the network from a miRNA to a gene. The score for an individual gene (G1) regulated by a miRNA is the sum of the edge scores ($S1 = a1 + b1 + c1$). To account for effects of more than one miRNA on an individual gene, we then computed a combined score representing the connectivity of the four miRNAs to G1. According to this scoring system, a higher rank is assigned to genes with strong connectivity of




Figure 4. Endocrine Cell-Enriched miRNAs Regulate a Network of Cell Cycle Genes

(A) Schematic of approach to identify core network of miRNA-regulated transcription factors and down-stream target genes. Building of network (left) and probing of network (right) is summarized. The nodes of the graph represent miRNAs (squares; Let-7g [purple], Let-7a [red], miR-200a [yellow], and miR-375 [green]), TFs (triangles), TF-binding regions (hexagons), and genes (circles).

(B) Predicted network of 40 highest scoring cell cycle genes based on network in (A) with miRNAs depicted as rectangles, TFs as triangles, and genes as ovals. TF, transcription factor; G, gene; S, score.

See also Figure S4, Tables S5, and S6.

individual miRNA-mediated paths and characterized by an effect of more than one miRNA (Figure S4B and Table S6). The resulting network of the 40 highest scoring cell cycle genes demonstrates direct connectivity of the four miRNAs with cell cycle regulators through several TFs, including *SOX12*, *RFX1*, *TP53*, *E2F2*, *MBD2*, *ZNF512B*, *ZNF783*, and *ZNF641* (Figure 4B). Of interest is the identification of *NEUROD1* as an indirect miRNA target of Let-7 miRNAs and miR200a. Neurod1 is a TF that has been shown to induce cell cycle exit and to regulate endocrine cell differentiation in model organisms (Ahnfelt-Ronne et al., 2007; Mutoh et al., 1998). Our network analysis identifies a core network of miRNAs, TFs as their putative direct targets, and down-stream genes with likely roles in cell cycle regulation and endocrine cell differentiation.




Figure 5. Endocrine Cell-Enriched miRNAs Regulate Cell Cycle Exit and Endocrine Cell Differentiation

(A) Workflow to test effects of miRNAs on cell proliferation and endocrine cell differentiation during the transition of hESC-derived pancreatic endoderm (PE) to the early endocrine (EN) cell stage. Early PE stage cells were transduced with a lentivirus expressing a polycistronic construct for the indicated miRNAs (poly-miR) and mCherry, cultured in 2D until the end of the PE stage, aggregated, differentiated in 3D to the EN stage, sectioned, and stained for Ki-67 and insulin (INS). (B) Representative images showing immunofluorescence staining for Ki-67 (left) and INS (right) together with mCherry and DAPI at the EN stage for control vector (top) or poly-miR (bottom) transduced aggregates. Scale bar, 50 μ m. (C and D) Percentage of Ki-67⁺ cells (C) and INS⁺ cells (D) in the mCherry⁺ cell population. Data are shown as mean \pm S.E.M. (n = 3 biological replicates, each dot represents cell counts in a single aggregate from one of three independent experiments). (E and F) Cells were sorted based on mCherry at the EN stage, RNA-seq analysis performed (n = 4 biological replicates), and differentially expressed genes in control and poly-miR transduced cells identified. Enriched GO categories (top) and log₂-fold change (FC) of exemplary genes (bottom) among genes down- (E, p < 0.05, permutation test) and up-regulated (F, p < 0.05, permutation test) by the poly-miR. *p < 0.05, Student's t test. See also [Figure S5](#) and [Table S7](#).

miRNAs Regulate Endocrine Cell Differentiation by Promoting Cell Cycle Exit

We next determined whether forced expression of Let-7g, Let-7a, miR-200a, and miR-375 represses cell cycle progression in hESC-derived pancreatic progenitor cells, as predicted by our computational analysis. We transduced PE cells with the poly-miR lentiviral construct and differentiated these cells for another 6 days as 3D aggregates to the early pancreatic endocrine (EN) stage, when insulin⁺ cells are first present ([Figure 5A](#)). Sectioned aggregates were then stained for the proliferation marker Ki-67. Consistent with our computational prediction, forced expression of the miRNAs reduced the percentage of Ki-67⁺ cells ([Figures 5B](#) and [5C](#)). The miRNAs likely exhibit their anti-proliferative effect in progenitors and not beta cells, as insulin⁺ cells in EN stage cultures were mostly Ki67⁻ in both control vector- and poly-miR-transduced aggregates ([Figure S5A](#)).

Since cell cycle exit and endocrine cell differentiation are tightly coupled ([Kim et al., 2015](#); [Miyatsuka et al., 2011](#); [Piccand et al., 2014](#)), we tested whether the reduction in Ki-67⁺ cells after miRNA over-expression was associated with an increase in the number of insulin⁺ cells. Indeed, we observed a higher percentage of insulin⁺ cells in aggregates expressing the poly-miR construct compared with vector-transduced aggregates ([Figures 5B](#) and [5D](#)). The bias of our culture conditions for the differentiation of insulin⁺ cells ([Figure S5B](#)) precluded quantification of other endocrine cell types. To further determine how Let-7g, Let-7a, miR-200a, and miR-375 over-expression affects gene expression at the EN stage, we conducted RNA-seq analysis of sorted mCherry⁺ cells. Consistent with the reduction in Ki67⁺ cells in poly-miR-transduced cultures ([Figure 5C](#)), genes associated with cell cycle regulation, such as *CCND1*, *CDK4*, and *PCNA*, were enriched among genes down-regulated (p < 0.05, permutation test) by forced miRNA expression ([Figure 5E](#) and [Tables S7A](#) and [S7B](#)). Up-regulated genes (p < 0.05, permutation test) comprised endocrine cell-characteristic genes involved in the regulation of insulin secretion and ion transport (e.g., *GLPR1*, *SYT1*, *CACNA1A*, *SLC2A1*) ([Figure 5F](#) and [Tables S7A](#) and [S7C](#)), further supporting the conclusion that Let-7g, Let-7a, miR-200a, and miR-375 promote endocrine cell differentiation. We note that insulin mRNA levels were slightly decreased rather than increased in poly-miR transduced cells ([Table S7A](#)), suggesting that miRNAs or their target genes could affect insulin protein levels at the posttranscriptional level. Taken together, our data support a model whereby endocrine-enriched Let-7g, Let-7a, miR-200a, and miR-375 are part of a gene regulatory network that triggers cell cycle exit to promote endocrine cell differentiation.

DISCUSSION

Here, we identified 14 miRNAs (Let-7g, Let-7a, Let-7f, Let-7b, miR-200a, miR-200c, miR-204, miR-99b, miR-141, miR-127, miR-7, miR-27b, miR-98, and miR-375), that are induced during human beta cell differentiation. We further studied five miRNAs (Let-7g, Let-7a, miR-200a, miR-375, and miR-127) with a high fold-change during endocrine cell differentiation and experimentally show that these miRNAs induce cell cycle exit in pancreatic progenitor cells. By constructing an integrated miRNA-gene regulatory network of endocrine cell differentiation, we show that these miRNAs likely contribute to endocrine cell differentiation by directly regulating different sets of cell cycle-associated TFs.

To analyze how islet cell-enriched miRNAs cooperate to drive endocrine cell differentiation, we developed a computational method to model the relationship of miRNAs, TFs, and miRNA-regulated genes. Our

computational model builds on a previously published approach for constructing miRNA regulatory networks (Gosline et al., 2016) and integrates chromatin state and expression data to build a multi-layer network. Our approach differs in a few key aspects from published methodologies. First, it incorporates predictions from both CLIP-seq data and TargetScan into a combined score that is assigned to network edges. In addition, our scoring system focuses on a set of miRNAs identified experimentally and weighs the number of miRNAs contributing to each path, accounting for potential synergistic effects of miRNAs on downstream gene expression changes. As such, the algorithm presented here can be applied to other cellular contexts with matching miRNA/mRNA/chromatin data and provides a useful framework for the prediction of miRNA effects.

We found that islet cell-enriched miRNAs Let-7g, Let-7a, miR-200a, miR-375, and miR-127 repress different transcripts involved in cell cycle regulation and therefore might synergize in driving cell cycle exit and endocrine cell differentiation. All four miRNAs have been implicated in the regulation of cell proliferation in other contexts. Like the Let-7 family miRNAs studied here, Let-7b inhibits proliferation and induces neural differentiation when over-expressed in neural progenitors (Zhao et al., 2010). Furthermore, Let-7b, miR-200a, and miR-375 have been shown to induce cell cycle arrest in tumor cells (Liu et al., 2012; Uhlmann et al., 2010; Wang et al., 2011). Likewise, acute over-expression of miR-375 in dedifferentiated beta cells reduces their proliferation and promotes their redifferentiation (Nathan et al., 2015). This anti-proliferative effect of miR-375 is opposite to observations in *miR-375*-deficient mice, which exhibit decreased beta cell proliferation (Poy et al., 2009). Since these mice carry a germline mutation of *miR-375*, it is possible that the observed decrease in beta cell proliferation is the consequence of a developmental defect rather than a reflection of miR-375 directly regulating inhibitors of cell cycle progression.

Pancreatic endocrine cell differentiation is tightly linked to cell cycle exit. In both mice and humans, endocrine cell differentiation depends on the TF NGN3 (encoded by *NEUROG3*) (Gradwohl et al., 2000; McGrath et al., 2015), which commits pancreatic progenitors to the endocrine lineage and promotes cell cycle exit by inducing the cell cycle inhibitors *Cdkn1a* (p21/CIP1) and *Pak3* (Miyatsuka et al., 2011; Piccand et al., 2014). We observed no effect of either combined or individual Let-7g, Let-7a, miR-200a, and miR-375 over-expression on *NEUROG3* mRNA levels (Tables S2A–S2D, S2F), suggesting that these miRNAs exert their effect on proliferation independent of NGN3. However, Let-7g, Let-7a, miR-200a, and miR-375 expression with the poly-miR construct significantly induced the NGN3 target gene and endocrine differentiation factor *NEUROD1* (Ahnfelt-Ronne et al., 2007). Based on our computational model, these miRNAs are predicted to modulate *NEUROD1* expression indirectly through down-regulation of *NEUROD1* upstream TFs. Given that *NEUROD1* can promote cell cycle exit through direct activation of *Cdkn1a* (Mutoh et al., 1998), miRNA-mediated modulation of *NEUROD1* levels likely contributes to the observed effect of islet-enriched miRNAs on cell proliferation and differentiation.

Gain- and loss-of-function studies in model organisms have shown that the repressive effects of miRNAs on their targets is mostly modest, which has led to the view that miRNAs act to fine-tune gene expression. Consistent with this view, we observed relatively small effects of miRNA over-expression on gene expression, cell proliferation, and endocrine cell differentiation. However, these results do not mean that the miRNAs are not important for endocrine cell differentiation. We over-expressed islet cell-enriched miRNAs in an *in vitro* system where growth factor conditions have been optimized for efficient beta cell differentiation. Therefore, the miRNAs might not be limiting in the context of these optimized conditions. Studies in model organisms underscore the idea that miRNAs confer robustness to developmental processes and become limiting only under conditions of stress. For example, loss of miR-7 has little effect on *Drosophila* sensory organ development under normal conditions, but when environmental stresses are added to the developing organism, miR-7 becomes necessary (Li et al., 2009). Similar examples exist in worms and mice, where miRNA deletions lead to significant developmental perturbations only on sensitized backgrounds or under stress (Brenner et al., 2010; Chivukula et al., 2014). Further illustrating that miRNAs can have significant biological effects in specific contexts, miRNAs have been shown to drastically augment reprogramming efficiencies (Anokye-Danso et al., 2011; Yoo et al., 2011). Therefore, the here-identified islet cell-enriched miRNAs could help develop still missing protocols for robust direct reprogramming of human endocrine cells.

Limitations of the Study

One limitation of our approach for identifying endocrine cell differentiation-relevant miRNAs is the focus on miRNAs that repress mRNAs. There is evidence that miRNAs can activate gene expression or directly

reduce protein levels (El Ouaamari et al., 2008; Jopling et al., 2008; Vasudevan et al., 2007). It is possible that some of the identified miRNAs regulate endocrine cell differentiation through these mechanisms. Another limitation is that we compared miRNA profiles in pancreatic progenitors and mature human endocrine cells. Therefore, we do not know how these miRNAs are regulated during postnatal endocrine cell maturation. Finally, our network modeling approach predicts synergist effects of Let-7g, Let-7a, miR-200a, and miR-375 on cell cycle regulation. This predicted synergy will have to be experimentally validated.

METHODS

All methods can be found in the accompanying [Transparent Methods supplemental file](#).

DATA AND CODE AVAILABILITY

All RNA-seq and ATAC-seq data generated in this study can be found at GEO with accession number GSE115327.

Accession numbers for additional data used in this study are as follows: GSE52314 (small RNA-seq, sorted alpha and beta cells); GSE51924 (CLIP-seq, human islets); E-MTAB-1086 (RNA-seq, PE cells); GSE54471 (H3K27ac, H3K4me3 ChIP-seq, PE cells); GSE51311, E-MTAB-1919, E-MTAB-189, and E-MTAB-191 (H3K27ac, H3K4me3 ChIP-seq, human islets).

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.isci.2019.10.063>.

ACKNOWLEDGMENTS

We thank Medhavi Mallick and Gaowei Wang for help with figure preparation. Human pancreatic islets were provided by the Integrated Islet Distribution Program (UC4 DK098085). We acknowledge the UCSD IGM Genomics Center for next-generation sequencing (P30 DK063491). This work was supported by the National Institutes of Health (R01 DK068471 and R01 DK078803 to M.S.), the California Institute for Regenerative Medicine (RB4-06144 to M.S.), and postdoctoral fellowships from the Juvenile Diabetes Research Foundation Ltd (3-2015-83 to W.J., 3-2012-177 to A.W., and 3-2017-386 to K.-V.N.-N.) and the Larry L. Hillblom Foundation (2015-D-021-FEL to B.G.).

AUTHOR CONTRIBUTIONS

W.J., F.M., and M.S. conceived the project and designed the experiments. W.J., B.G., J.W., C.Z., K.-V.N.-N., I.M., and H.-P.S. performed experiments. F.M., Y.S., A.W., and J.C. conducted bioinformatics analysis. N.V. contributed ATAC-seq analysis, K.H.K. provided small RNA-seq data, and K.A.F. provided islet RNA-seq and islet ATAC-seq data. W.J., F.M., B.G., and M.S. interpreted data. W.J., F.M., A.C.C., and M.S. wrote the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: October 3, 2018

Revised: September 30, 2019

Accepted: October 28, 2019

Published: November 22, 2019

REFERENCES

- Ahnfelt-Ronne, J., Hald, J., Bodker, A., Yassin, H., Serup, P., and Hecksher-Sorensen, J. (2007). Preservation of proliferating pancreatic progenitor cells by Delta-Notch signaling in the embryonic chicken pancreas. *BMC Dev. Biol.* 7, 63.
- Anokye-Danso, F., Trivedi, C.M., Juhr, D., Gupta, M., Cui, Z., Tian, Y., Zhang, Y., Yang, W., Gruber, P.J., Epstein, J.A., et al. (2011). Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. *Cell Stem Cell* 8, 376–388.
- Belgardt, B.F., Ahmed, K., Spranger, M., Latreille, M., Denzler, R., Kondratiuk, N., von Meyenn, F., Villena, F.N., Herrmanns, K., Bosco, D., et al. (2015). The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes. *Nat. Med.* 21, 619–627.
- Benthuisen, J.R., Carrano, A.C., and Sander, M. (2016). Advances in beta cell replacement and regeneration strategies for treating diabetes. *J. Clin. Invest.* 126, 3651–3660.
- Brenner, J.L., Jasiewicz, K.L., Fahley, A.F., Kemp, B.J., and Abbott, A.L. (2010). Loss of individual microRNAs causes mutant phenotypes in sensitized genetic backgrounds in *C. elegans*. *Curr. Biol.* 20, 1321–1325.

- Chen, C.Z., Li, L., Lodish, H.F., and Bartel, D.P. (2004). MicroRNAs modulate hematopoietic lineage differentiation. *Science* 303, 83–86.
- Chen, J.F., Mandel, E.M., Thomson, J.M., Wu, Q., Callis, T.E., Hammond, S.M., Conlon, F.L., and Wang, D.Z. (2006). The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. *Nat. Genet.* 38, 228–233.
- Chivukula, R.R., Shi, G., Acharya, A., Mills, E.W., Zeitels, L.R., Anandam, J.L., Abdelnaby, A.A., Balch, G.C., Mansour, J.C., Yopp, A.C., et al. (2014). An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration. *Cell* 157, 1104–1116.
- Creyghton, M.P., Cheng, A.W., Welstead, G.G., Kooistra, T., Carey, B.W., Steine, E.J., Hanna, J., Lodato, M.A., Frampton, G.M., Sharp, P.A., et al. (2010). Histone H3K27ac separates active from poised enhancers and predicts developmental state. *Proc. Natl. Acad. Sci. U S A* 107, 21931–21936.
- Dey, B.K., Gagan, J., Yan, Z., and Dutta, A. (2012). miR-26a is required for skeletal muscle differentiation and regeneration in mice. *Genes Dev.* 26, 2180–2191.
- El Ouaamari, A., Baroukh, N., Martens, G.A., Lebrun, P., Pipeleers, D., and van Obberghen, E. (2008). miR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. *Diabetes* 57, 2708–2717.
- Gosline, S.J., Gurtan, A.M., JnBaptiste, C.K., Bosson, A., Milani, P., Dalin, S., Matthews, B.J., Yap, Y.S., Sharp, P.A., and Fraenkel, E. (2016). Elucidating MicroRNA regulatory networks using transcriptional, post-transcriptional, and histone modification measurements. *Cell Rep.* 14, 310–319.
- Gradwohl, G., Dierich, A., LeMeur, M., and Guillemot, F. (2000). *neurogenin3* is required for the development of the four endocrine cell lineages of the pancreas. *Proc. Natl. Acad. Sci. U S A* 97, 1607–1611.
- Guo, H., Ingolia, N.T., Weissman, J.S., and Bartel, D.P. (2010). Mammalian microRNAs predominantly act to decrease target mRNA levels. *Nature* 466, 835–840.
- Heintzman, N.D., Hon, G.C., Hawkins, R.D., Kheradpour, P., Stark, A., Harp, L.F., Ye, Z., Lee, L.K., Stuart, R.K., Ching, C.W., et al. (2009). Histone modifications at human enhancers reflect global cell-type-specific gene expression. *Nature* 459, 108–112.
- Jopling, C.L., Schutz, S., and Sarnow, P. (2008). Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. *Cell Host Microbe* 4, 77–85.
- Kameswaran, V., Bramswig, N.C., McKenna, L.B., Penn, M., Schug, J., Hand, N.J., Chen, Y., Choi, I., Vourekas, A., Won, K.J., et al. (2014). Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. *Cell Metab.* 19, 135–145.
- Kaspi, H., Pasvolosky, R., and Hornstein, E. (2014). Could microRNAs contribute to the maintenance of beta cell identity? *Trends Endocrinol. Metab.* 25, 285–292.
- Kim, Y.H., Larsen, H.L., Rue, P., Lemaire, L.A., Ferrer, J., and Grapin-Botton, A. (2015). Cell cycle-dependent differentiation dynamics balances growth and endocrine differentiation in the pancreas. *PLoS Biol.* 13, e1002111.
- Kloosterman, W.P., Lagendijk, A.K., Ketting, R.F., Moulton, J.D., and Plasterk, R.H. (2007). Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. *PLoS Biol.* 5, e203.
- Kredo-Russo, S., Mandelbaum, A.D., Ness, A., Alon, I., Lennox, K.A., Behlke, M.A., and Hornstein, E. (2012). Pancreas-enriched miRNA refines endocrine cell differentiation. *Development* 139, 3021–3031.
- Latreille, M., Hausser, J., Stutzer, I., Zhang, Q., Hastoy, B., Gargani, S., Kerr-Conte, J., Pattou, F., Zavolan, M., Esguerra, J.L., et al. (2014). MicroRNA-7a regulates pancreatic beta cell function. *J. Clin. Invest.* 124, 2722–2735.
- Li, X., Cassidy, J.J., Reinke, C.A., Fischboeck, S., and Carthew, R.W. (2009). A microRNA imparts robustness against environmental fluctuation during development. *Cell* 137, 273–282.
- Lim, L.P., Lau, N.C., Garrett-Engle, P., Grimson, A., Schelter, J.M., Castle, J., Bartel, D.P., Linsley, P.S., and Johnson, J.M. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. *Nature* 433, 769–773.
- Liu, C., Kelnar, K., Vlassov, A.V., Brown, D., Wang, J., and Tang, D.G. (2012). Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. *Cancer Res.* 72, 3393–3404.
- Lynn, F.C., Skewes-Cox, P., Kosaka, Y., McManus, M.T., Harfe, B.D., and German, M.S. (2007). MicroRNA expression is required for pancreatic islet cell genesis in the mouse. *Diabetes* 56, 2938–2945.
- Matsuda, H., Mullapudi, S.T., Zhang, Y., Hesselton, D., and Stainier, D.Y.R. (2017). Thyroid hormone coordinates pancreatic islet maturation during the zebrafish Larval-to-Juvenile transition to maintain glucose homeostasis. *Diabetes* 66, 2623–2635.
- McGrath, P.S., Watson, C.L., Ingram, C., Helmrath, M.A., and Wells, J.M. (2015). The basic helix-loop-helix transcription factor *NEUROG3* is required for development of the human endocrine pancreas. *Diabetes* 64, 2497–2505.
- Melkman-Zehavi, T., Oren, R., Kredo-Russo, S., Shapira, T., Mandelbaum, A.D., Rivkin, N., Nir, T., Lennox, K.A., Behlke, M.A., Dor, Y., et al. (2011). miRNAs control insulin content in pancreatic beta-cells via downregulation of transcriptional repressors. *EMBO J.* 30, 835–845.
- Miyatsuka, T., Kosaka, Y., Kim, H., and German, M.S. (2011). *Neurogenin3* inhibits proliferation in endocrine progenitors by inducing *Cdkn1a*. *Proc. Natl. Acad. Sci. U S A* 108, 185–190.
- Mutuh, H., Naya, F.J., Tsai, M.J., and Leiter, A.B. (1998). The basic helix-loop-helix protein *BETA2* interacts with *p300* to coordinate differentiation of secretin-expressing enteroendocrine cells. *Genes Dev.* 12, 820–830.
- Nam, Y.J., Song, K., Luo, X., Daniel, E., Lambeth, K., West, K., Hill, J.A., DiMaio, J.M., Baker, L.A., Bassel-Duby, R., et al. (2013). Reprogramming of human fibroblasts toward a cardiac fate. *Proc. Natl. Acad. Sci. U S A* 110, 5588–5593.
- Nathan, G., Kredo-Russo, S., Geiger, T., Lenz, A., Kaspi, H., Hornstein, E., and Efrat, S. (2015). MiR-375 promotes redifferentiation of adult human beta cells expanded in vitro. *PLoS One* 10, e0122108.
- Nieto, M., Hevia, P., Garcia, E., Klein, D., Alvarez-Cubela, S., Bravo-Egana, V., Rosero, S., Damaris Molano, R., Vargas, N., Ricordi, C., et al. (2012). Antisense miR-7 impairs insulin expression in developing pancreas and in cultured pancreatic buds. *Cell Transplant.* 21, 1761–1774.
- Piccand, J., Meunier, A., Merle, C., Jia, Z., Barnier, J.V., and Gradwohl, G. (2014). Pak3 promotes cell cycle exit and differentiation of beta-cells in the embryonic pancreas and is necessary to maintain glucose homeostasis in adult mice. *Diabetes* 63, 203–215.
- Poy, M.N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., Macdonald, P.E., Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P., et al. (2004). A pancreatic islet-specific microRNA regulates insulin secretion. *Nature* 432, 226–230.
- Poy, M.N., Hausser, J., Trajkovski, M., Braun, M., Collins, S., Rorsman, P., Zavolan, M., and Stoffel, M. (2009). miR-375 maintains normal pancreatic alpha- and beta-cell mass. *Proc. Natl. Acad. Sci. U S A* 106, 5813–5818.
- Rezania, A., Bruin, J.E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O'Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., et al. (2014). Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. *Nat. Biotechnol.* 32, 1121–1133.
- Schaffer, A.E., Taylor, B.L., Benthuisen, J.R., Liu, J., Thorel, F., Yuan, W., Jiao, Y., Kaestner, K.H., Herrera, P.L., Magnuson, M.A., et al. (2013). *Nkx6.1* controls a gene regulatory network required for establishing and maintaining pancreatic Beta cell identity. *PLoS Genet.* 9, e1003274.
- Taylor, B.L., Liu, F.F., and Sander, M. (2013). *Nkx6.1* is essential for maintaining the functional state of pancreatic beta cells. *Cell Rep.* 4, 1262–1275.
- Uhlmann, S., Zhang, J.D., Schwager, A., Mannsperger, H., Riazalhosseini, Y., Burmester, S., Ward, A., Korf, U., Wiemann, S., and Sahin, O. (2010). miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. *Oncogene* 29, 4297–4306.
- Valinezhad Orang, A., Safaralizadeh, R., and Kazemzadeh-Bavili, M. (2014). Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. *Int. J. Genomics* 2014, 970607.
- Vasudevan, S., Tong, Y., and Steitz, J.A. (2007). Switching from repression to activation:

microRNAs can up-regulate translation. *Science* 318, 1931–1934.

Vidigal, J.A., and Ventura, A. (2015). The biological functions of miRNAs: lessons from in vivo studies. *Trends Cell Biol.* 25, 137–147.

Wang, A., Yue, F., Li, Y., Xie, R., Harper, T., Patel, N.A., Muth, K., Palmer, J., Qiu, Y., Wang, J., et al. (2015). Epigenetic priming of enhancers predicts developmental competence of hESC-derived endodermal lineage intermediates. *Cell Stem Cell* 16, 386–399.

Wang, F., Li, Y., Zhou, J., Xu, J., Peng, C., Ye, F., Shen, Y., Lu, W., Wan, X., and Xie, X. (2011). miR-

375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. *Am. J. Pathol.* 179, 2580–2588.

Wang, Y., Liu, J., Liu, C., Najj, A., and Stoffers, D.A. (2013). MicroRNA-7 regulates the mTOR pathway and proliferation in adult pancreatic beta-cells. *Diabetes* 62, 887–895.

Xie, R., Everett, L.J., Lim, H.W., Patel, N.A., Schug, J., Kroon, E., Kelly, O.G., Wang, A., D'Amour, K.A., Robins, A.J., et al. (2013). Dynamic chromatin remodeling mediated by polycomb proteins orchestrates pancreatic differentiation

of human embryonic stem cells. *Cell Stem Cell* 12, 224–237.

Yoo, A.S., Sun, A.X., Li, L., Shcheglovitov, A., Portmann, T., Li, Y., Lee-Messer, C., Dolmetsch, R.E., Tsien, R.W., and Crabtree, G.R. (2011). MicroRNA-mediated conversion of human fibroblasts to neurons. *Nature* 476, 228–231.

Zhao, C., Sun, G., Li, S., Lang, M.F., Yang, S., Li, W., and Shi, Y. (2010). MicroRNA let-7b regulates neural stem cell proliferation and differentiation by targeting nuclear receptor TLX signaling. *Proc. Natl. Acad. Sci. U S A* 107, 1876–1881.

Supplemental Information

**A Network of microRNAs Acts to Promote
Cell Cycle Exit and Differentiation
of Human Pancreatic Endocrine Cells**

Wen Jin, Francesca Mulas, Bjoern Gaertner, Yinghui Sui, Jinzhao Wang, Ileana Matta, Chun Zeng, Nicholas Vinckier, Allen Wang, Kim-Vy Nguyen-Ngoc, Joshua Chiou, Klaus H. Kaestner, Kelly A. Frazer, Andrea C. Carrano, Hung-Ping Shih, and Maïke Sander

Supplemental figures and legends

Figure S1




Figure S1: Pancreatic endoderm differentiated from CyT49 hESCs. Related to Figure 1.

(A) Schematic of the hESC-based differentiation strategy. **(B)** Immunofluorescence staining of PE cell aggregate sections for PE-specific markers PDX1 and SOX9. Scale bar, 50 μ m. **(C)** Representative flow cytometry analysis at PE stage for PDX1. hESC, human embryonic stem cells; DE, definitive endoderm; GT, gut tube; FG posterior foregut; PE, pancreatic endoderm; EN, endocrine cell stage.

Figure S2




Figure S2. Forced expression of individual miRNAs in hESC-derived pancreatic progenitor cells. Related to Figure 2.

(A) Immunofluorescence staining of pancreatic endoderm (PE) differentiated from H1 hESCs for PDX1 and SOX9. Scale bar, 50 μm . **(B)** Representative flow cytometry analysis at PE stage for PDX1. **(C)** Scatter plot showing correlation in mRNA expression between PE cells derived from H1 hESCs and CyT49 hESCs. **(D)** Expression of indicated miRNAs in H1-derived PE cells and islets relative to CyT49-derived PE cells determined by Taqman qPCR. Data are shown as mean \pm S.E.M. (n = 3 technical replicates). **(E)** Representative flow cytometry analysis for mCherry 48 h (top row) and 6 days (bottom row) after lentiviral transduction with miRNA-mCherry constructs. Gating for cell sorting is shown. **(F)** Relative expression of indicated miRNAs determined by Taqman qPCR in H1 PE cells 48 h after lentiviral transduction with miRNAs or vector control (C). Data are shown as mean \pm S.E.M. (n = 3 biological replicates). ** $P < 0.01$, *** $P < 0.001$; Student's t-test. **(G)** GSEA plots showing enrichment of genes repressed by Let-7g, Let-7a, miR-200a, miR-375, and miR-127 in islets (n = 3) compared to PE (n = 2). False Discovery Rate (FDR) is shown.

Figure S3





Figure S3. Forced expression of a polycistronic construct for four miRNAs in hESC-derived pancreatic progenitor cells. Related to Figure 3.


(A) Representative flow cytometry analysis for mCherry 48 h (left) and 6 days (right) after lentiviral transduction with poly-miR-mCherry construct. Gating for cell sorting is shown. **(B)** Relative expression of indicated miRNAs determined by Taqman qPCR in H1 PE cells 48 h after lentiviral transduction with a vector control or a polycistronic construct containing Let-7g, Let-7a, miR-200a, and miR-375 (poly-miR). Data are shown as mean \pm S.E.M. ($n = 3$ biological replicates). $**P < 0.01$, $***P < 0.001$; Student's t-test. **(C)** GSEA plot showing enrichment of genes repressed by the poly-miR construct in islets compared to PE. False Discovery Rate (FDR) is shown. **(D)** Venn diagram showing the overlap between genes down-regulated in islets compared to PE (blue) and genes repressed by the poly-miR construct (grey). Top five GO categories enriched among genes repressed by the poly-miR construct and down-regulated in islets compared to PE are shown on the bottom.

Figure S4

A



B



C




Figure S4. Approach to identify core network of miRNA-regulated genes in pancreatic progenitor cells. Related to Figure 4.

(A,B) Schematic of approach to identify core network of miRNA-regulated transcription factors and cell cycle genes. Building of network **(A)** and probing of network **(B)** is shown. The nodes of the graph represent miRNAs [squares; Let-7g (purple), Let-7a (red), miR-200a (yellow), and miR-375 (green)], transcription factors (triangles), transcription factor binding regions (hexagons) and genes (circles). In **(A)**, the source for each node is indicated on the left, while evidence (indicated by *a*, *b*, and *c*) used to calculate scores is indicated on the right. In **(B)**, path-based scoring of an individual gene [e.g. gene 1 (G1)] is shown. See Materials and Methods for details. **(C)** Top five GO categories enriched in genes comprising the miRNA-regulated core network in **(A)**. TF, transcription factor; G, gene; S, score.

Figure S5




Figure S5. Endocrine cell differentiation from H1 hESCs. Related to Figure 5. **(A)** Representative images showing immunofluorescence staining for insulin (INS), Ki-67, mCherry, and DAPI at the endocrine cell (EN) stage for control vector (top) or poly-miR (bottom) transduced aggregates. **(B)** Immunofluorescence staining of sections from EN stage aggregates for insulin (INS), glucagon (GCG), and somatostatin (SST). Scale bar, 50 μ m.

Transparent Methods

Contact for reagent and resource sharing

Further information and requests for reagents may be directed and will be fulfilled by the corresponding author Maike Sander (masander@ucsd.edu).

Experimental model and subject details

Human islets

Human cadaveric pancreatic islets for the Taqman miRNA analysis (Donor ID:1-3) and for the RNA-seq and ATAC-seq analysis (Donor ID: 4-7) were obtained through the Integrated Islet Distribution Program (IIDP). The islets had $\geq 90\%$ purity and $\geq 90\%$ viability. Upon receipt, islets were handpicked and immediately processed for RNA extraction or isolation of nuclei.

Donor ID	Donor Age	Donor Sex	Diabetes*	BMI	Race	Cause of Death
1	53	Male	No	27.2	Caucasian	CVA/STROKE
2	48	Female	No	31.0	American Indian or Alaska Native	CVA/STROKE
3	48	Male	No	27.7	Caucasian	CVA/STROKE
4	55	Male	No	29.8	Black or African American	CVA/STROKE
5	59	Female	No	24.7	Caucasian	CNS tumor
6	55	Male	No	23.2	Caucasian	Head trauma
7	56	Female	No	33.4	Black or African American	CVA/STROKE

*Diabetes status was defined by the patient's medical record and, when available, hemoglobin A1c levels.

Maintenance and differentiation of H1 hESCs

hESC research was approved by the University of California, San Diego, Institutional Review Board and Embryonic Stem Cell Research Oversight Committee. All hESC experiments were performed in H1 hESCs with the exception of miRNA expression profiling, for which CyT49 hESCs were used.

H1 hESCs were maintained and differentiated as described with some modifications (Rezania et al., 2014). In brief, hESCs were cultured in mTeSR1 media (Stem Cell Technologies) and propagated by passaging cells every 3 to 4 days using Accutase (eBioscience) for enzymatic cell dissociation. For differentiation of H1 cells, we employed a 2D monolayer culture format up to day 11 of differentiation. Cells were then dissociated using accutase for 10 min, reaggregated by plating the cells in a low attachment 6-well plate on an orbital shaker (100 rpm) in a 37 °C incubator. Cells were subsequently cultured in suspension from Days 11-14.

On Day 0, dissociated hESCs were resuspended in mTeSR1 media (see media compositions below) and seeded onto Matrigel-coated 12-well plates by adding 1 ml of cell suspension ($\sim 8 \times 10^5$ cells/well) to each well. The following day, undifferentiated cells were washed in stage 1 medium and then differentiated using a multi-step protocol with stage-specific media (see below) and daily media changes.

All stage-specific base media were comprised of MCDB 131 medium (Thermo Fisher Scientific) supplemented with NaHCO₃, GlutaMAX, D-Glucose, and BSA using the following concentrations:

Stage 1/2 medium: MCDB 131 medium, 1.5 g/L NaHCO₃, 1X GlutaMAX, 10 mM D-Glucose, 0.5% BSA

Stage 3/4 medium: MCDB 131 medium, 2.5 g/L NaHCO₃, 1X GlutaMAX, 10 mM D-glucose, 2% BSA

Stage 5 medium: MCDB 131 medium, 1.5 g/L NaHCO₃, 1X GlutaMAX, 20 mM D-glucose, 2% BSA

Media compositions for each stage were as follows:

Stage 1 (Days 0-2): base medium, 100 ng/ml Activin A, 25 ng/ml Wnt3a (Day 0).

Day 1-2: base medium, 100 ng/ml Activin A

Stage 2 (Days 3-5): base medium, 0.25 mM L-Ascorbic Acid (Vitamin C), 50 ng/mL FGF7

Stage 3 (Days 6-7): base medium, 0.25 mM L-Ascorbic Acid, 50 ng/mL FGF7, 0.25 μM SANT-1, 1 μM Retinoic Acid, 100 nM LDN193189, 1:200 ITS-X, 200 nM TPB

Stage 4 (Days 8-10): base medium, 0.25 mM L-Ascorbic Acid, 2 ng/mL FGF7, 0.25 μM SANT-1, 0.1 μM Retinoic Acid, 200 nM LDN193189, 1:200 ITS-X, 100nM TPB

Stage 5 (Days 11-14): base medium, 0.25 μ M SANT-1, 0.05 μ M Retinoic Acid, 100 nM LDN193189, 1:200 ITS-X, 1 μ M T3, 10 μ M ALK5 inhibitor II, 10 μ M ZnSO₄, and 10 μ g/mL Heparin, 10 μ M ROCK inhibitor

End of stage 1 = definitive endoderm

End of stage 2 = gut tube

End of stage 3 = posterior foregut

End of stage 4 = pancreatic endoderm

End of stage 5 = endocrine cells

Maintenance and differentiation of CyT49 hESCs

CyT49 hESCs were maintained and differentiated as described (Xie et al., 2013). Propagation of CyT49 hESCs was carried out by passing cells every 3 to 4 days using Accutase™ (eBioscience) for enzymatic cell dissociation, and with 10% (v/v) human AB serum (Valley Biomedical) included in the hESC medium the day of passage. hESCs were seeded into tissue culture flasks at a density of 50,000 cells/cm².

CyT49 hESC medium was comprised of DMEM/F12 (Corning; 45000-346) supplemented with 10% (v/v) KnockOut™ Serum Replacement (Thermo Fisher Scientific), 1X MEM non-essential amino acids (Thermo Fisher Scientific), 1X GlutaMAX™ (Thermo Fisher Scientific), 1% (v/v) penicillin-streptomycin (Thermo Fisher Scientific), 0.1mM 2-mercaptoethanol (Thermo Fisher Scientific), 10ng/mL Activin A (R&D Systems), and 10ng/mL Heregulin- β 1 (PeproTech).

Pancreatic differentiation of CyT49 hESCs was performed as previously described (Schulz et al., 2012). Briefly, we employed a suspension-based format using rotational culture. Undifferentiated hESCs were aggregated by preparing a single-cell suspension in hESC media at 1×10^6 cells/mL and overnight culture in six-well ultra-low attachment plates (Costar) with 5.5ml per well on an orbital rotator (Innova2000, New Brunswick Scientific) at 95 rpm. The following day, undifferentiated aggregates were washed in RPMI media (Corning) and then differentiated using a multistep protocol with daily media changes and continued orbital rotation at either 95 rpm or at 105 rpm on Days 4 to 8.

Stage 1/2 medium: RPMI medium (Corning), 0.2 % (vol/vol) FBS, 1X GlutaMAX

Stage 3/4 medium: DMEM High Glucose medium (HyClone), 0.5X B-27 Supplement, 1X GlutaMAX

Media compositions for each stage were as follows:

Stage 1 (Days 0-1): Day 0: RPMI/FBS, 100ng/mL Activin A, 50ng/mL mouse Wnt3a, 1:5000 ITS. Day 1: RPMI/FBS, 100 ng/mL Activin A, 1:5000 ITS

Stage 2 (Days 2-4): Day 2: RPMI/FBS, 2.5 μ M TGF β R1 kinase inhibitor IV, 25ng/mL KGF, 1:1000 ITS. Days 3-4: RPMI/FBS, 25ng/mL KGF, 1:1000 ITS

Stage 3 (Days 5 -7): DMEM/B27, 3nM TTNPB, 0.25mM KAAD-Cyclopamine, 50ng/mL Noggin

Stage 4 (Days 7-10): DMEM/B27, 50ng/mL KGF, 50ng/mL EGF

End of stage 1 = definitive endoderm

End of stage 2 = gut tube

End of stage 3 = posterior foregut

End of stage 4 = pancreatic endoderm

Cell line

HEK293T cells were maintained in DMEM containing 100 units/mL penicillin and 100 mg/mL streptomycin sulfate supplemented with 10% fetal bovine serum (FBS).

Method details

Immunocytochemistry

Cells were washed twice before fixation with 4% paraformaldehyde in PBS for either 30 min at room temperature, or overnight at 4°C. Cells were then washed three times with PBS and incubated in 30% sucrose at 4°C overnight before mounting in Optimal Cutting Temperature Compound (Tissue-Tek) and sectioning at 10 µm. Immunocytochemistry was performed as described (Xie et al., 2013). The following primary antibodies and dilutions were used: guinea pig anti-PDX1 (gift from Dr. Christopher Wright, Vanderbilt University) 1:1000; rabbit anti-SOX9 (Millipore, AB5535) 1:1000; rabbit anti-Ki-67 (ThermoFisher, RM-9106-S1) 1:200; guinea pig anti-insulin (LINCO, 4011-01) 1:1000. Secondary antibodies were Cy5-, Cy3-, or Alex488-conjugated donkey antibodies against guinea pig or rabbit (Jackson Immuno Research Laboratories). Images were

acquired on a Zeiss Axio-Observer-Z1 microscope with a Zeiss AxioCam digital camera and figures prepared with Adobe Photoshop CS6/Illustrator CS5.

To determine the percentage of Ki-67⁺ cells in the mCherry⁺ cell population, at least ten sections from different aggregates were analyzed per hPSC differentiation. For each condition, three independent hPSC differentiations were performed. Ki-67⁺ and mCherry⁺ cells were quantified using HALO software (PerkinElmer Inc).

Fluorescence-activated cell sorting and intracellular flow cytometry

hESC-derived PE cells were dissociated to a single-cell suspension with Accutase (Stemcell Technologies) at 37°C for 10 min. Accutase was neutralized with FACS sorting buffer [1% (wt/vol) FBS, 1 mM EDTA, 25mM HEPES, PBS]. FACS was performed on a FACS Fortessa equipped with FACS Diva software (BD Biosciences). Cells were sorted into Trizol for RNA analysis. For intracellular flow cytometry, dissociated cells were fixed, permeabilized with BD Cytoperm/Cytofix (BD Bioscience), and stained with anti-PDX1-PE conjugated antibody (BD Biosciences, 562161; 1:20) at room temperature for 30 min, washed, and resuspended in FACS buffer. Flow cytometry analysis was performed on FACSCanto II (BD Biosciences) and analyzed with FlowJo software (FlowJo LLC).

TaqMan microRNA assay

qRT-PCR for miRNAs was performed using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Cat. No. 4366596). Briefly, 10 ng of total RNA was reverse transcribed using RT primers from the TaqMan MicroRNA Assay kit [Applied Biosystems; probe catalogue numbers: Let-7a (000377), Let-7g (002282), miR-127 (000452), miR-200a (000502), miR-375 (000564), miR-7 (000268), miR-99b (000436), and RUN44 (001094)]. qRT-PCR was performed on a Bio-rad CFX96 real-time system using the TaqMan Universal PCR Master Mix (Applied Biosystems, Cat. No. 4324018) and TaqMan probes from the TaqMan MicroRNA Assay kit. miRNA levels were determined on three independent samples and values were normalized to endogenous snoRNA RNU44.

miRNA expression vector construction

To generate miRNA expression vectors, 270 nt of the miRNA gene primary transcript, including the 22 nt mature miRNA and 125 nt of genomic sequence flanking each side of the miRNA (Chen et al., 2004), were amplified. Let-7a and Let-7g were expressed with mutations in their loop sequence to block LIN28 binding and ensure proper miRNA processing (Piskounova et al., 2008). For transduction of PE cells, a modified version of pLKO.3G was used, in which GFP was exchanged for mCherry (pLKO.mcherry). For the polycistronic miRNA expression vector, a gBlock gene fragment encompassing miR-375, Let-7a, Let-7g, and miR-200a was cloned into pLKO.mcherry.

Lentivirus production and transduction of PE cells

High-titer lentiviral supernatants were generated by co-transfection of the miRNA expression vector and the lentiviral packaging construct into HEK293T cells as described (Xie et al., 2013). Briefly, miRNA expression vectors were cotransfected with the pCMV-R8.74 (Addgene, #22036) and pMD2.G (Addgene, #12259) expression plasmids into HEK293T cells using a 1mg/ml PEI solution (Polysciences). Lentiviral supernatants were collected at 48 hr and 72 hr after transfection. Lentiviruses were concentrated by ultracentrifugation for 120 min at 19,500 rpm using a Beckman SW28 ultracentrifuge rotor at 4°C. The titer routinely achieved was $5 \times 10^8 \sim 10^9$ TU/ml. For PE cell transductions, H1 hESCs were differentiated to the PE stage (Day 8 of differentiation) in monolayer cultures and transduced with lentivirus at a MOI of 2. For RNA analysis, cells were collected 48 hr after transduction.

Small RNA sequencing and data analysis

Small RNA-seq data from sorted human alpha and beta cells have been described (Kameswaran et al., 2014). RNA from PE stage CyT49 hESC cultures was isolated using the miRVana miRNA Isolation kit (Thermo Fisher Scientific). 3 µg of RNA was used for library preparation using the TruSeq Small RNA sample preparation kit (Illumina) and a Pippin Prep (Sage Science) for size selection with a 3% cassette (CSD3010). RNA was prepared for sequencing using the Illumina protocol (Illumina FC-102-1009) and amplified libraries were sequenced on an Illumina Genome Analyzer II (Illumina FC-104-1003). Sequenced libraries were

processed as described (Kameswaran et al., 2014). miRNAs with sample values below 1 RPM were excluded from the analysis. There was one replicate each for hESC-derived PE, alpha, and beta cells. Each miRNA expression value was log₂-transformed and displayed in a heatmap.

RNA sequencing, mapping and data analysis

RNA quality was assessed using TapeStation (Agilent Technologies). Libraries were prepared according to the instructions of Illumina's TruSeq RNA library prep kit. Libraries were quantified using High Sensitivity DNA screen tape (Agilent Technologies) and Qubit dsDNA High Sensitivity (Life Technologies) assays. Finally, libraries were multiplexed and sequenced on a HiSeq 2500 (Illumina) sequencer using single-end sequencing.

RNA-seq samples were mapped to the UCSC human transcriptome (hg19/GRCh37) by the Spliced Transcripts Alignment to a Reference (STAR) aligner (STAR-STAR_2.4.0f1), allowing for up to 10 mismatches (Dobin et al., 2013). Only reads aligned uniquely to one genomic location were retained for subsequent analysis. Expression levels of all genes were quantified by Cufflink (<https://github.com/cole-trapnell-lab/cufflinks>) using only reads with exact matches. Genes with average RPKM above 1 were retained for further analyses.

Differentially expressed genes were identified using a permutation test, with the number of permutations set to 1000. Briefly, all the samples were shuffled, fold changes were computed to obtain a null distribution, and a *P*-value was estimated for each gene's fold change as a cumulative probability from the

null distribution. For comparison of PE and islet data and poly-miR versus control data at the EN stage, batch effects were removed using ComBat (Johnson et al., 2007).

Gene Set Enrichment Analysis (GSEA) and Gene Ontology (GO) analysis

We applied GSEA (<http://www.broad.mit.edu/gsea>), which scores a-priori defined gene sets in two different conditions (Subramanian et al., 2005). GSEA (<http://www.broad.mit.edu/gsea>) was run with the number of permutations for *P*-value computation set to 1000. We used genes significantly repressed by miRNAs ($P < 0.05$, permutation test) as gene sets to determine coordinated regulation in islets compared to PE samples. Gene sets with a false discovery rate of < 0.05 were considered significantly enriched. Enrichment of gene sets for Gene Ontology (GO) terms was tested using Metascape (Tripathi et al., 2015).

ATAC-seq sample preparation

Roughly 50,000 PE or primary human islet cells were used for each ATAC-seq assay as described (Buenrostro et al., 2013). Briefly, cell nuclei were isolated using cold lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl₂ and 0.1% IGEPAL CA-630). The nuclei pellet was resuspended in the transposase reaction mix; 25 μ L 2x TD buffer, 2.5 μ L transposase (Illumina) and 22.5 μ L nuclease-free water at 37°C for 30 min. Then transposed DNA fragments were purified using the Qiagen MinElute kit and amplified 10-12 cycles using the

Nextera (Illumina) PCR primers. Libraries were sequenced on HiSeq4000 platform.

ChIP-seq and ATAC-seq data analysis

ChIP-seq and ATAC-seq reads were mapped to the human genome (hg19/GRCh37) using Bowtie (Langmead et al., 2009) and BWA (Li and Durbin, 2009), respectively, and visualized using the UCSC Genome Browser (Kent et al., 2002). Unmapped reads were discarded. After mapping, SAMtools (Li et al., 2009) was used to remove duplicate sequences and merge samples. Here, "SAMtools view -Sbq 30" was used to filter out reads with mapping quality less than 30, "SAMtools rmdup" was used to remove duplicated reads, and "SAMtools merge" was used to merge files of the same histone marker or input condition. ChIP-seq and ATAC-seq analysis was performed in two biological replicates for PE and 4-5 donors for islet. The Pearson correlation among biological replicates ranged from 64% to 96% for human islets and 91% to 96% for PE.

HOMER (Heinz et al., 2010) as used to call ChIP-seq peaks using "findPeaks function" with "-style histone" to call peaks. Stage- and condition-matched input DNA controls were used as background when calling peaks. MACS2 (Zhang et al., 2008) was used to call peaks from ATAC-seq data, with parameters "shift set to 100 bps, smoothing window of 200 bps" and with "nolambda" and "nomodel" flags on.

To link changes in chromatin to gene expression changes, we first defined differential H3K27ac and H3K4me3 peaks in PE and islet (adjusted $P < 0.05$,

“getDifferentialPeaksReplicates” function in HOMER) and then used BEDtools (Quinlan and Hall, 2010) to identify overlapping ATAC peaks in PE or islet using a ± 1.5 kb window from the summit of the ATAC peak. Next, we identified the nearest TSS within a 10kb window of the H3K27ac or H3K4me3 peak. We then assessed the concordance of the directionality of changes in gene expression and histone marks by evaluating whether genes near regions showing gain or loss of H3K27ac or H3K4me3 in PE versus islet exhibit significant concordant expression changes (Mann-Whitney test).

Network building

CLIP-seq signal, mRNA expression, ATAC-seq and ChIP-seq binding data were encoded in a graphical model depicted in Figures 4 and Figure S4 by adapting a previously published algorithm (Gosline et al., 2016). Nodes arranged in four different layers, corresponding to miRNAs, transcription factors (TFs), DNA regions, and genes, were identified and connected as follows: For each of the four selected miRNAs, predicted target genes were retrieved through the TargetScan repository (http://www.targetscan.org/vert_71/). For the pairs of miRNA-target gene identified, the corresponding CLIP-seq signal was collected from previously published data (Kameswaran et al., 2014). Among the targets, TFs in the second layer of the network were selected based on down-regulation by poly-miR transfection compared to control with $P < 0.05$ and with an annotation in the TF Animal Database (Zhang et al., 2015). In the third layer of the network, we selected DNA regions showing significant changes in PE versus

islet for H3K27ac or H3K4me3 (see previous paragraph) with the nearest gene showing down-regulation by poly-miR transfection, hereafter referred to as *Rsel*. The *Rsel* DNA regions were filtered for links to the selected TFs by scoring the match of their binding motifs with the DNA regions in the network. Briefly, motifs of selected TFs were extracted from a collection of databases, including JASPAR (http://jaspar.genereg.net/cgi-bin/jaspar_db.pl), Hocomoco (<http://hocomoco11.autosome.ru/>), and ENCODE-related data sets (Aylward et al., 2018) and scored for matches with narrow regions spanning 300bp around the peak summits of each *Rsel*. Log-odds scores and corresponding *P*-values were obtained using the MEME Suite tool FIMO (<http://meme-suite.org/tools/fimo>) with default parameters. The last layer was defined by considering genes proximal to DNA regions, as described above, and filtering for those differentially regulated in poly-miR versus control ($P < 0.05$).

A score representing the strength of the association was computed for each pair of connected nodes in the different network layers, as follows: Given the TargetScan context++ score S_i (Agarwal et al., 2015) and the CLIP-seq signal S_j of each miRNA-TF association, their values were normalized in a 0-1 range and combined as $a = (1 - S_i)(1 - S_j)$ (Szklarczyk et al., 2015). Scores of edges connecting TFs to *Rsel* regions were defined as $b = 1 - q$, q being the *q*-value returned by FIMO, representing the probability of obtaining the log-odds ratio scores of the matches by chance. Scores from DNA regions to genes were defined as the absolute value of the Log2 Fold Change of each gene x in poly-miR versus control data: $c = |Log2FC(x)|$. A combined score was computed for

each possible path in the network starting from a miRNA to a gene, by adding the contribution of the different layers, as: $S = a + b + c$.

Network-based gene ranking

Given an individual gene, G1, all network paths connecting a miRNA to G1 were considered with their corresponding scores and compared for gene ranking as follows: Among the paths connecting the same miRNA to G1, only the one with the highest score was retained, obtaining a score S_i for each of the k miRNAs showing an indirect link to G1, $k \leq N$, with N equal to the number of miRNAs in the network ($N=4$). A first score summarizing the strength of the association of these retrieved network paths was computed as $S_{net}(G1) = mean(S_i)$, i ranging from one to k . A second score, accounting for the synergistic effect of several miRNAs on the same gene, was computed as proportion of miRNAs in at least one network path linking to the selected gene G1: $S_{mir}(G1) = k/N$. Finally, a combined score for G1 was obtained as a weighted sum of S_{net} and S_{mir} , i.e. $S_{comb}(G_1) = w * S_{net}(G1) + w * S_{mir}(G1)$, with w set to 0.5. This procedure was applied to score individual genes annotated to cell cycle regulation in the Gene Ontology (GO:0051726) and genes were ranked based on S_{comb} values.

Quantification and statistical analysis

Statistical parameters including FDR, R, and P -values are reported in the Figures and the Figure Legends.

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Rabbit anti-PDX1	Abcam	Cat# ab47267, RRID:AB_777179
Rabbit anti-SOX9	Millipore	Cat# AB5535, RRID:AB_2239761
Guinea pig anti-INS	Dako	Cat# A0564, RRID:AB_10013624
Mouse anti-GCG	Sigma-Aldrich	Cat# G2654, RRID:AB_259852
Rabbit anti-SST	Agilent	Cat# A056601-2
Mouse anti-Ki67	Lab Vision	Cat# RM-9106-S1, RRID:AB_149792
Mouse anti-PDX1, PE conjugate	BD Biosciences	Cat# 562161, RRID:AB_10893589
Mouse IgG1, kappa isotype control (PE conjugate)	BD Biosciences	Cat# 556650, RRID:AB_396514
Chemicals, Peptides, and Recombinant Proteins		
DPBS	Corning	Cat# 45000-434
Fatty Acid-Free BSA	Proliant Biologicals	Cat# 68700
D-(+)-Glucose Solution, 45%	Sigma-Aldrich	Cat# G8769
Accutase®	eBioscience	Cat# 00-4555-56
Penicillin-Streptomycin	Thermo Fisher Scientific	Cat# 15140122
GlutaMAX™	Thermo Fisher Scientific	Cat# 35050061
MEM Non-Essential Amino Acids Solution (100X)	Thermo Fisher Scientific	Cat# 11140050
Sodium Bicarbonate	Sigma-Aldrich	Cat# NC0564699
Matrigel®	Corning	Cat# 356231
ROCK Inhibitor Y-27632	STEMCELL Technologies	Cat# 72305
mTeSR1 Complete Kit - GMP	STEMCELL Technologies	Cat# 85850
RPMI 1640 1X, w/o L-Glutamine	Corning	Cat# 45000-404
DMEM/F12 with L-Glutamine, HEPES	Corning	Cat# 45000-350
DMEM/F12 w/o L-Glutamine	Corning	Cat# 45000-346
HyClone Dulbecco's Modified Eagles Medium	Thermo Fisher Scientific	Cat# SH30081.FS
MCDB 131	Thermo Fisher Scientific	Cat# 10372-019
CTS™ KnockOut™ SR XenoFree Kit	Thermo Fisher Scientific	Cat# A1099202
Insulin-Transferrin-Selenium (ITS-G) (100X)	Thermo Fisher Scientific	Cat# 41400045
Insulin-Transferrin-Selenium-Ethanolamine (ITS-X) (100X)	Thermo Fisher Scientific	Cat# 51500-056
B-27™ Supplement (50X)	Thermo Fisher Scientific	Cat# 17504044

Bovine Albumin Fraction V (7.5%)	Thermo Fisher Scientific	Cat# 15260037
2-Mercaptoethanol	Thermo Fisher Scientific	Cat# 21985-023
Human AB Serum	Valley Biomedical	Cat# HP1022
Activin A	R&D Systems	Cat# 338-AC/CF
Heregulin β -1	Peprtech	Cat# 100-03
ALK5 Inhibitor II	Enzo Life Sciences	Cat# ALX-270-445
KGF/FGF7	R&D Systems	Cat# 251-KG
EGF	R&D Systems	Cat# 236-EG
Retinoic Acid	Sigma-Aldrich	Cat# R2625
LDN-193189	Stemgent	Cat# 04-0074
SANT-1	Sigma-Aldrich	Cat# S4572
TPB	Calbiochem	Cat# 565740
Noggin	R&D Systems	Cat# 3344-NG-050
Wnt3a	R&D Systems	Cat# 1324-WN-010
3,3',5-Triiodo-L-thyronine sodium salt (T3)	Sigma-Aldrich	Cat# T6397
TGF β R1 kinase inhibitor IV	EMD Biosciences	Cat# 616454
KAAD-Cyclopamine	Toronto Research Chemicals	Cat# K171000
Heparin	Sigma-Aldrich	Cat# H3149
TTNPB	Sigma-Aldrich	Cat# T3757
Zinc Sulfate	Sigma-Aldrich	Cat# Z0251
TRIzol®	Thermo Fisher Scientific	Cat# 15596018
Polyethylenimine (PEI)	Polysciences	Cat# 23966-1
O.C.T. Compound	Sakura Finetek USA	Cat# 25608-930
Vectashield Antifade Mounting Medium	Vector Laboratories	Cat# H-1000
Critical Commercial Assays		
MinElute Reaction Cleanup Kit	QIAGEN	Cat#28204
miRNeasy Mini Kit	QIAGEN	Cat# 74104
mirVana™ miRNA Isolation Kit	Thermo Fisher Scientific	Cat# AM1560
Nextera DNA Library Preparation Kit (24 samples)	Illumina	Cat#FC-121-1030
TruSeq Stranded mRNA Library Preparation Kit	Illumina	Cat# 20020594
TruSeq Small RNA Library Preparation Kit	Illumina	Cat# RS-200-0012
RNA 6000 Nano Kit	Agilent Technologies	Cat# 5067-1511
High Sensitivity D1000 ScreenTape	Agilent Technologies	Cat# 5067-5584
RNA ScreenTape	Agilent Technologies	Cat# 5067-5576
RNA ScreenTape Sample Buffer	Agilent Technologies	Cat# 5067-5577
RNA ScreenTape Ladder	Agilent Technologies	Cat# 5067- 5578
Qubit ssDNA assay kit	Thermo Fisher Scientific	Cat# Q10212
iScript™ cDNA Synthesis Kit	Bio-Rad	Cat# 1708890
iQ™ SYBR® Green Supermix	Bio-Rad	Cat# 1708880
Cytofix/Cytoperm W/Golgi Stop Kit	BD Biosciences	Cat# 554715

Deposited Data		
RNA-seq and ATAC-seq data	GEO	GSE115327
Experimental Models: Cell Lines		
H1	WiCell Research Institute	NIHhESC-10-0043, RRID:CVCL_9771
CyT49	ViaCyte, Inc.	NIHhESC-10-0041, RRID:CVCL_B850
HEK293T	ATCC	Cat# CRL-3216, RRID:CVCL_0063
Oligonucleotides		
Assay ID: 000377, Taqman miRNA assay; hsa-let-7a	Thermo Fisher Scientific	Cat# 4427975
Assay ID: 002282, Taqman miRNA assay; hsa-let-7g	Thermo Fisher Scientific	Cat# 4427975
Assay ID: 000452, Taqman miRNA assay; hsa-miR127- 3p	Thermo Fisher Scientific	Cat# 4427975
Assay ID: 000502, Taqman miRNA assay; hsa-miR- 200a-3p	Thermo Fisher Scientific	Cat# 4427975
Assay ID: 002300, Taqman miRNA assay; hsa-miR- 200c-3p	Thermo Fisher Scientific	Cat# 4427975
Assay ID: 000377, Taqman miRNA assay; hsa-let-7a	Thermo Fisher Scientific	Cat# 4427975
Assay ID: 000564, Taqman miRNA assay; hsa-miR-375	Thermo Fisher Scientific	Cat# 4427975
Assay ID: 000268, Taqman miRNA assay; hsa-miR-7- 5p	Thermo Fisher Scientific	Cat# 4427975
Assay ID: 000436, Taqman miRNA assay; hsa-miR- 99b-5p	Thermo Fisher Scientific	Cat# 4427975
Assay ID: 001182, Taqman miRNA assay; hsa-miR- 124-3p	Thermo Fisher Scientific	Cat# 4427975
Assay ID: 001094, Taqman miRNA assay; RNU control	Thermo Fisher Scientific	Cat# 4427975

<p>ATTTgaattctcagccgcagatgcgttcaggtgagggcggaggctagcg gggcgctgtgcagcactgagctcgcggaagaccaggaccaggagatca c cgagggcgaccgccaggccccggccctccgctccccccccgcgacga gcccctgcacaaaccggacctgagcgtttgttcgctcggctcgcgtgagg cagggcgccctctcagcaccagcccggggccggcctgatgccacgc aggcacctgccgcccaccgccaccgccatctcaaccgtacgggtggg agaggctgtgcgccgctccaggggagatccggctccatccggccccacc cgccctgccttgccctgcccgcagcttctTTCTTATCACTCACACA GGAAACCAGGATTACCGAGGAGGAAAAAAGCCTT CCTGTGGTGCTCAACTGTGATTCCTTTTCACCATTC ACCCTGGATGTTCTCTTCACTGTGGGATGAGgtAGT A GGTTGTATAGTTctgttgaatctcatggACTATAACAATCTAC TGTCTTTCCTAACGTGATAGAAAAGTCTGCATCCAG CGGTCTGATAGAAAAGTCAGTAACTAATTGTACAA TATTTAAGATTAACCTGTCTTAAAGAGATGTAGTGC A GCATTTGTTTATGGCCTGGAATAAATTAATTTAGA G ATAAAGTCTGTAGCAAGTACACTGGATGGGctccaaat gtggtgcaagatgaggcaaatgtgtggcactgtagctttgctgccaagcctc tgctgtgaggatgttcccttctgtctcaagtgcacctgaagagtccctccag cgctccgtttcctttgctgattccaggctgaggtagtagttgtacagttctgtt gaatctcatggctgtacaggccactgcctgccaggaacagcgcgccagct gccaagtggggctgagaggatggcgtcacctgctcatctctgggaaacc a ggtaatggggaggaagtcCACCACCCCTGGCTGCTCACCG CTCCGGTTCTTCCCTGGGCTTCCACAGCAGCCCCT GCCTGCCTGGCGGGACCCACGTCCTCCCGGGC CCCTGTGAGCATTTACCGGACAGTGCTGGATTTTC C CAGCTTGACTCTAACACTGTCTGGTAACGATGTTCA AAGGTGACCCGCCGCTCGCCGGGGACACCACCGA GGCACATCCGGAGCTCCTACTCCAGGGATGGGCTG TTTTTTttaattaaGGTG</p>	This study	IDT gBlock
Software and Algorithms		
Flowjo-v10	FlowJo LLC	http://www.flowjo.com/download-newest-version/
STAR 2.4.0f1	(Dobin et al., 2013)	https://github.com/alexdobin/STAR
Bowtie 1.1.1	(Langmead et al., 2009)	http://bowtie-bio.sourceforge.net/index.shtml
Cufflinks 2.2.1	(Trapnell et al., 2010)	https://github.com/cole-trapnell-lab/cufflinks
HTSeq 0.6.1	(Anders et al., 2015)	https://htseq.readthedocs.io/en/master/install.html
DESeq2 1.10.1	(Love et al., 2014)	https://www.bioconductor.org/packages/development/bioc/html/DESeq2.html
MACS2	(Zhang et al., 2008)	http://liulab.dfci.harvard.edu/MACS/Download.html

BEDTools 2.17.0	(Quinlan and Hall, 2010)	https://bedtools.readthedocs.io/en/latest/content/installation.html
ComBat (part of the sva Bioconductor package)	(Johnson et al., 2007) (Leek, 2014)	http://bioconductor.org/packages/release/bioc/html/sva.html
GSEA	(Mootha et al., 2003; Subramanian et al., 2005)	http://www.broad.mit.edu/gsea
Metascape	(Tripathi et al., 2015)	http://metascape.org/gp/index.html#/main/step1
TargetScan	(Agarwal et al., 2015)	http://www.targetscan.org/vert_72/
JASPAR	(Khan et al., 2018)	http://jaspar.genereg.net/cgi-bin/jaspar_db.pl
Hocomoco	(Kulakovskiy et al., 2018)	http://hocomoco11.automosome.ru/
FIMO	(Grant et al., 2011)	http://meme-suite.org/tools/fimo
R 3.5.0		https://cran.r-project.org/
SAMtools 1.3	(Li et al., 2009)	https://github.com/samtools/samtools
HOMER 4.10	(Heinz et al., 2010)	http://homer.ucsd.edu/homer/download.html
HALO™ Image Analysis Software	PerkinElmer	http://www.perkinelmer.com/product/halo-plus-3-ws-license-cls141255
Adobe Illustrator CS5		
Adobe Photoshop CS5		

Supplemental References

- Agarwal, V., Bell, G.W., Nam, J.W., and Bartel, D.P. (2015). Predicting effective microRNA target sites in mammalian mRNAs. *Elife* 4.
- Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq--a Python framework to work with high-throughput sequencing data. *Bioinformatics* 31, 166-169.
- Aylward, A., Chiou, J., Okino, M., Kadakai, N., and Gaulton, K.J. (2018). Shared genetic contribution to type 1 and type 2 diabetes risk. *bioRxiv*.
- Buenrostro, J.D., Giresi, P.G., Zaba, L.C., Chang, H.Y., and Greenleaf, W.J. (2013). Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nature methods* 10, 1213-1218.
- Chen, C.Z., Li, L., Lodish, H.F., and Bartel, D.P. (2004). MicroRNAs modulate hematopoietic lineage differentiation. *Science* 303, 83-86.
- Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15-21.
- Gosline, S.J., Gurtan, A.M., JnBaptiste, C.K., Bosson, A., Milani, P., Dalin, S., Matthews, B.J., Yap, Y.S., Sharp, P.A., and Fraenkel, E. (2016). Elucidating MicroRNA Regulatory Networks Using Transcriptional, Post-transcriptional, and Histone Modification Measurements. *Cell Rep* 14, 310-319.
- Grant, C.E., Bailey, T.L., and Noble, W.S. (2011). FIMO: scanning for occurrences of a given motif. *Bioinformatics* 27, 1017-1018.
- Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., Singh, H., and Glass, C.K. (2010). Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Molecular cell* 38, 576-589.
- Johnson, W.E., Li, C., and Rabinovic, A. (2007). Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics* 8, 118-127.
- Kameswaran, V., Bramswig, N.C., McKenna, L.B., Penn, M., Schug, J., Hand, N.J., Chen, Y., Choi, I., Vourekas, A., Won, K.J., *et al.* (2014). Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. *Cell metabolism* 19, 135-145.
- Khan, A., Fornes, O., Stigliani, A., Gheorghe, M., Castro-Mondragon, J.A., van der Lee, R., Bessy, A., Cheneby, J., Kulkarni, S.R., Tan, G., *et al.* (2018). JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. *Nucleic Acids Res* 46, D260-D266.
- Kent, W.J., Sugnet, C.W., Furey, T.S., Roskin, K.M., Pringle, T.H., Zahler, A.M., and Haussler, D. (2002). The human genome browser at UCSC. *Genome Res* 12, 996-1006.
- Kulakovskiy, I.V., Vorontsov, I.E., Yevshin, I.S., Sharipov, R.N., Fedorova, A.D., Rumynskiy, E.I., Medvedeva, Y.A., Magana-Mora, A., Bajic, V.B., Papatsenko, D.A., *et al.* (2018). HOCOMOCO: towards a complete collection of transcription factor binding models for human and mouse via large-scale ChIP-Seq analysis. *Nucleic Acids Res* 46, D252- D259.
- Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* 10, R25.
- Leek, J.T. (2014). svaseq: removing batch effects and other unwanted noise from sequencing data. *Nucleic Acids Res* 42.

- Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25, 1754-1760.
- Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., and Genome Project Data Processing, S. (2009). The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078-2079.
- Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15, 550.
- Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E., et al. (2003). PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nature genetics* 34, 267-273.
- Piskounova, E., Viswanathan, S.R., Janas, M., LaPierre, R.J., Daley, G.Q., Sliz, P., and Gregory, R.I. (2008). Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. *J Biol Chem* 283, 21310-21314.
- Quinlan, A.R., and Hall, I.M. (2010). BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* 26, 841-842.
- Rezania, A., Bruin, J.E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O'Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., et al. (2014). Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. *Nat Biotechnol* 32, 1121-1133.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 102, 15545-15550.
- Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K.P., et al. (2015). STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Res* 43, D447-452.
- Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M.J., Salzberg, S.L., Wold, B.J., and Pachter, L. (2010). Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat Biotechnol* 28, 511-515.
- Tripathi, S., Pohl, M.O., Zhou, Y., Rodriguez-Frandsen, A., Wang, G., Stein, D.A., Moulton, H.M., DeJesus, P., Che, J., Mulder, L.C., et al. (2015). Meta- and Orthogonal Integration of Influenza "OMICS" Data Defines a Role for UBR4 in Virus Budding. *Cell Host Microbe* 18, 723-735.
- Xie, R., Everett, L.J., Lim, H.W., Patel, N.A., Schug, J., Kroon, E., Kelly, O.G., Wang, A., D'Amour, K.A., Robins, A.J., et al. (2013). Dynamic chromatin remodeling mediated by polycomb proteins orchestrates pancreatic differentiation of human embryonic stem cells. *Cell Stem Cell* 12, 224-237.
- Zhang, H.M., Liu, T., Liu, C.J., Song, S., Zhang, X., Liu, W., Jia, H., Xue, Y., and Guo, A.Y. (2015). AnimalTFDB 2.0: a resource for expression, prediction and functional study of animal transcription factors. *Nucleic Acids Res* 43, D76-81.
- Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W., et al. (2008). Model-based analysis of ChIP-Seq (MACS). *Genome Biol* 9, R137.